Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04602767 · ClinicalTrials.gov registry record · Phase 4
Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery
A Phase 4 study of Acute Kidney Injury, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT04602767 is a Phase 4 study of Acute Kidney Injury that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 300 participants, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04602767, a Phase 4 study of Acute Kidney Injury, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, open label study to investigate vasopressin versus phenylephrine as a first line pressor in cardiac surgery. All patients \>18 years of age presenting for coronary artery bypass graft (CABG), valve surgery, or combined CABG and valve surgery will be screened for inclusion. Patients with ejection fraction \< 35%, \> moderate pulmonary hypertension, \> mild right ventricular dysfunction, a planned radial arterial graft, or circulatory arrest will be excluded. Patients will be randomized to receive either vasopressin or phenylephrine as the first line vasopressor during the perioperative period to maintain mean arterial blood pressure \>65 mmhg. Primary outcome is acute kidney injury. Secondary outcomes are 30-day mortality, stroke, myocardial infarction, re-operation, sternal infection, atrial fibrillation, intensive care unit length of stay, and total vasopressor hours.
Conditions Studied
Interventions
- DRUG Vasopressin
- DRUG Phenylephrine
Study Locations (1)
Pennsylvania
- Thomas Jefferson Univesity - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04602767
The ClinicalTrials.gov registry entry for NCT04602767 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,327-participant average among 74 other Acute Kidney Injury trials with a reported enrollment target (87% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Vasopressin is the first listed.
NCT04602767 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04602767 about?
NCT04602767 is a clinical study titled "Low Dose Vasopressin vs Phenylephrine in Cardiac Surgery". This is a randomized, open label study to investigate vasopressin versus phenylephrine as a first line pressor in cardiac surgery. All patients \>18 years of age presenting for coronary artery bypass graft (CABG), valve surgery, or combined CABG and valve surgery will be screened for inclusion. Pati...
What is the current status of trial NCT04602767?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2020-10-15. Estimated completion is 2024-10-01.
What conditions does trial NCT04602767 study?
This clinical trial studies the following conditions: Acute Kidney Injury.
What interventions are being tested in trial NCT04602767?
The interventions under investigation include: Vasopressin (DRUG), Phenylephrine (DRUG).
Who is sponsoring clinical trial NCT04602767?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04602767 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients
RECRUITING · Phase 4
-
Ultra-Low Contrast Angiography in AKI
RECRUITING · Phase 3
-
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
RECRUITING
-
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
RECRUITING
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.